Mustang Bio, Inc. (NASDAQ:MBIO – Get Free Report) shares traded down 8.6% during trading on Tuesday. The company traded as low as $0.3748 and last traded at $0.3768. 29,692 shares changed hands during trading, a decline of 23% from the average daily volume of 38,460 shares. The stock had previously closed at $0.4124.
Analysts Set New Price Targets
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Mustang Bio in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.
Check Out Our Latest Stock Report on Mustang Bio
Mustang Bio Stock Down 8.6%
Mustang Bio (NASDAQ:MBIO – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($140.00) by $139.84.
Institutional Inflows and Outflows
An institutional investor recently bought a new stake in Mustang Bio stock. BlackRock Inc. purchased a new position in shares of Mustang Bio, Inc. (NASDAQ:MBIO – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 84,745 shares of the company’s stock, valued at approximately $59,000. BlackRock Inc. owned about 1.12% of Mustang Bio as of its most recent SEC filing. 9.95% of the stock is currently owned by hedge funds and other institutional investors.
About Mustang Bio
Mustang Bio, Inc is a clinical-stage biotechnology company focused on developing cell and gene therapies for cancer and other serious diseases. The company has historically operated as a subsidiary of Fortress Biotech and has concentrated on engineered T-cell therapies designed to recognize and attack specific tumor targets.
Its development programs have included MB-106, an investigational CD20-targeted CAR T-cell therapy for certain B-cell malignancies, and MB-101, an investigational CAR T-cell therapy targeting IL13Rα2 for glioblastoma and other central nervous system tumors.
Recommended Stories
- Five stocks we like better than Mustang Bio
- A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?
- Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity?
- Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow Runway
- Tesla’s Robotaxi Lands in Paris—But Europe’s Real Fight Is Over Cheap EVs
Receive News & Ratings for Mustang Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mustang Bio and related companies with MarketBeat.com's FREE daily email newsletter.
